Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: MK 341; NU3450; Rizaben; SB 252218

Latest Information Update: 12 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kissei Pharmaceutical
  • Developer Kissei Pharmaceutical; Nuon Therapeutics
  • Class Anthranilic acids; Antiallergics; Antiasthmatics; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action Collagen inhibitors; Immunomodulators; Mast cell stabilisers; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-myc modulators; SLC2A9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Allergic conjunctivitis; Allergic rhinitis; Asthma; Atopic dermatitis; Hypertrophic scars; Keloids
  • Discontinued Cancer metastases; Coronary artery restenosis; Hyperuricaemia; Multiple sclerosis; Rheumatoid arthritis; Vascular restenosis

Most Recent Events

  • 31 Dec 2010 Nuon Therapeutics completes a phase II trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Germany, Mexico, Serbia & United Kingdom
  • 28 May 2010 Tranilast is still in phase II trials for Rheumatoid arthritis worldwide except Japan and South Korea (http://www.kissei.co.jp/e_contents/relation/pipeline.html)
  • 24 Jul 2007 Kissei Pharmaceutical and Nuon Therapeutics enter into a licensing, supply and collaboration agreement for tranilast
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top